By targeting the Pg-protein interactions with various cell signaling pathways implicated in cancer, such as PI3K/Akt, MAPK/ERK, and NF-kB pathways along with downregulating the expression of pro-angiogenic factors namely, VEGF by these enantiomers may facilitate in their anticancer activity. This evidence concerns the gene JUP and cancer.